LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 28

Search options

  1. Article ; Online: Clinical findings and immunophenotypic profile of plasma cell leukemia

    Nurgul Ozcan / Semih Basci / Eda Ozcan / Mehmet Bakirtas / Mehmet Sinan Dal / Merih Kizil Cakar / Fatma Meric Yilmaz / Fevzi Altuntas

    Medicine Science, Vol 10, Iss 2, Pp 455-

    a retrospective study in a comprehensive cancer center in Turkey

    2021  Volume 61

    Abstract: Plasma cell leukemia (PCL) is a rare (1-2 %) aggressive plasma cell dyscrasia (PCD) with a poor prognosis and characterized by the presence of more than 20% circulating plasma cells (PCs). Multicolor Flowcytometry is used for differentiating PCs in PCL. ... ...

    Abstract Plasma cell leukemia (PCL) is a rare (1-2 %) aggressive plasma cell dyscrasia (PCD) with a poor prognosis and characterized by the presence of more than 20% circulating plasma cells (PCs). Multicolor Flowcytometry is used for differentiating PCs in PCL. In this study, we aimed to compare the clinical, laboratory findings and immunophenotypic profiles of patients with PCL. A total of 512 patients were investigated for PCD in our hospital between 2011-2019. The immunophenotypic profile (including, CD27, CD28, CD38, CD138, CD45, CD117, CD19, CD20, CD56, CD33, CD81, and ckappa /clambda,) were evaluated retrospectively. The clinical findings, pathology reports, immunofixation electrophoresis and MFC results of three patients with PCL were reevaluated using 6 color multiparametric flow cytometry (MFC). Only three patients were diagnosed as PCL. PCs population defined by the co-expression of CD38 and CD138 was observed as 50%, 53%, 60%, respectively. Expression of each CD56, CD117, CD20, CD45 was seen in individual cases. CD19 was negative in all cases. Cytoplasmic kappa light chain expression was detected only in one case. Two of the cases were primary and the other was secondary PCL. Bortezomib-based treatment was initiated. Overall survival of primary PCL cases were 24 months and 6 months, whereas secondary PCL was four months. Co-expression of CD38 and CD138 in identifying PCs with MFC may be considered the best combination and leads to early diagnosis within hours and appropriate treatment in patients with PCL. [Med-Science 2021; 10(2.000): 455-61]
    Keywords plasma cell leukemia ; immunophenotype ; cd38 ; cd138 ; cd56 ; cd117 ; Medicine ; R ; Medicine (General) ; R5-920
    Subject code 610
    Language English
    Publishing date 2021-06-01T00:00:00Z
    Publisher Society of TURAZ AKADEMI
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?

    Bahar UNCU ULU / Derya ŞAHİN / Tuğçe Nur YİĞENOĞLU / Merih KIZIL ÇAKAR / Mehmet Sinan DAL / Fevzi ALTUNTAŞ

    Namık Kemal Tıp Dergisi, Vol 9, Iss 2, Pp 207-

    2021  Volume 212

    Abstract: Aim:Outcome for most patients with peripheral T cell lymphomas (PTCLs) is poor, with low response rates and short durations of remission. We aim to analyze the outcome of PTCL patients who underwent autologous stem cell transplantation (ASCT) at our ... ...

    Abstract Aim:Outcome for most patients with peripheral T cell lymphomas (PTCLs) is poor, with low response rates and short durations of remission. We aim to analyze the outcome of PTCL patients who underwent autologous stem cell transplantation (ASCT) at our center and we researched whether first complete remission (CR) was the optimal timing for ASCT in patients with PTCL.Materials and Methods:The data of PTCL patients who underwent ASCT between January 2010 and December 2020 at our center were retrospectively analyzed.Results:Twenty-five patients with PTCL underwent ASCT. The median ASCT age was 44 years (range: 19-68). 68% of the patients were performed upfront ASCT after the first CR; 32% of the patients underwent ASCT after relapse or refractory (R/R) disease. The median follow-up time from diagnosis was 40 months (13-144 months). The five-year PFS and OS were 50.8% and 55.7%, respectively. Five-year OS was 82.4% in the up-front ASCT group, while the five-year OS was 15.6% in the R/R patients (p=0.019). The median OS was 25 months [95% confidence interval (CI): 0-50.4] in patients who had CR2, while it was 13 months (95% CI: 0-35) in patients who had PR before ASCT (p=0.03). According to subtypes of PTCL, OS and PFS were not statistically different in all groups (p=0.96 and p=0.79, respectively). Conclusion:Even the prognosis is poor in patients with PTCL, Overall survival was significantly longer among the upfront ASCT group. Patients should be consolidated with ASCT in the first CR, and relapse should not be waited to perform ASCT.
    Keywords peripheral t cell lymphoma ; ptcl ; autologous stem cell transplantation ; upfront asct ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2021-08-01T00:00:00Z
    Publisher Galenos Yayincilik
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Tyrosine kinase inhibitors and COVID-19.

    Semih, Başcı / Tuğçe Nur, Yiğenoğlu / Mehmet Sinan, Dal / Serdal, Korkmaz / Burhan, Turgut / Fevzi, Altuntaş

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

    2020  Volume 26, Issue 8, Page(s) 2072–2073

    MeSH term(s) COVID-19 ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Pandemics ; Protein Kinase Inhibitors/adverse effects ; SARS-CoV-2
    Chemical Substances Protein Kinase Inhibitors
    Keywords covid19
    Language English
    Publishing date 2020-10-21
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 1330764-2
    ISSN 1477-092X ; 1078-1552
    ISSN (online) 1477-092X
    ISSN 1078-1552
    DOI 10.1177/1078155220967081
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4488: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Peripheral stem cell mobilization strategies in patients with autologous hematopoietic cell transplantation

    SİNEM NAMDAROĞLU / Tugçe Nur Yigenoglu / Hikmettullah Batgi / Bahar Uncu Ulu / Dicle İskender / Merih Çakar / Mehmet Sinan Dal / Fevzi Altuntaş

    Jurnal Teknologi Laboratorium, Vol 9, Iss 2, Pp 159-

    A single center's experience

    2020  Volume 167

    Abstract: This research is to investigate the parameters which may affect the mobilization of stem cells in patients receiving autologous hematopoietic peripheral blood stem cell transplantation (PBSCT). A retrospective study was carried out using the data derived ...

    Abstract This research is to investigate the parameters which may affect the mobilization of stem cells in patients receiving autologous hematopoietic peripheral blood stem cell transplantation (PBSCT). A retrospective study was carried out using the data derived from the medical files of 242 patients who received PBSCT. Descriptive, clinical, and laboratory parameters were compared between patients with successful and unsuccessful stem cell mobilization. Successful stem cell mobilization ratio was 4.463 times higher when preemptive plerixafor was administrated; 1.032 times higher when CD34+ cell count increased 1 unit at the beginning of mobilization. The white blood cell count was inversely correlated with the success of mobilization. An increase of 1 unit in WBC count was associated with a 1.027 times decrease in the success rate. The data indicated that the administration of preemptive plerixafor and CD34+ cell count at the beginning of mobilization were directly related to the success of mobilization after PBSCT. On contrary, WBC count was inversely associated with the success rate.
    Keywords bone marrow ; hematopoietic peripheral ; stem cell transplantation ; stem cell mobilization ; Medicine (General) ; R5-920
    Subject code 610 ; 571
    Language Indonesian
    Publishing date 2020-12-01T00:00:00Z
    Publisher Poltekkes Kemenkes Yogyakarta
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION WITH ACTIVE DISEASE IN ACUTE MYELOID LEUKEMIA

    Mehmet Bakirtas / Tugce Nur Yigenoglu / Semih Basci / Bahar Uncu Ulu / Nurgul Ozcan / Merih Kizil Cakar / Mehmet Sinan Dal / Fevzi Altuntas

    Sanamed, Vol 15, Iss 1, Pp 15-

    2020  Volume 19

    Abstract: Introduction: Despite multiple lines of chemotherapy, some patients with acute myeloid leukemia (AML) can not achieve remission. The prognosis of these patients is quite poor and they should be evaluated for clinical trials, otherwise myeloablative ... ...

    Abstract Introduction: Despite multiple lines of chemotherapy, some patients with acute myeloid leukemia (AML) can not achieve remission. The prognosis of these patients is quite poor and they should be evaluated for clinical trials, otherwise myeloablative conditioning regimens followed by allogeneic stem cell transplantation (Allo-SCT) should be performed to over come the active disease which is resistant to conventional doses and as it is the only curative option. Method: In this study, we evaluated the outcome of AML patients who underwent Allo-SCT with active disease in our center retrospectively. Results: A total of 161 AML patients underwent Allo-SCT between December 2009 and November 2018 at our center. 130 of them underwent Allo-SCT in complete remission while 31 of 161 had to undergo Allo-SCT with active disease due to refractoriness to salvage therapies. The median overall survival (OS) was7.9±2.8 months. 6-month OS was 25% and 1-year OS was only 6%. Progression-free survival (PFS) was 3.53±1.1 months. The transplant-related mortality rate was12.8%. Conclusion: OS and PFS are short in patients who undergo Allo-SCT with active diseases on oveltreatment approaches and targeted therapies should be developed to overcome active disease that are refractory to conventional chemotherapies.
    Keywords refractory acute myeloid leukemia ; allogeneic hematopoietic stemcell transplantation ; salvage therapy ; Medicine (General) ; R5-920
    Subject code 610
    Language English
    Publishing date 2020-06-01T00:00:00Z
    Publisher Association of medical doctors Sanamed Novi Pazar
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Autologous Stem Cell Transplantation in Multiple Myeloma Patients Over 60 Years Old

    Bahar Uncu Ulu / Tuğçe Nur Yiğenoğlu / Semih Başcı / Mehmet Bakırtaş / Derya Şahin / Tahir Darçın / Jale Yıldız / Alparslan Merdin / Nuran Ahu Baysal / Dicle İskender / Mehmet Sinan Dal / Merih Kızıl Çakar / Fevzi Altuntaş

    Medical Laboratory Technology Journal, Vol 7, Iss 1, Pp 18-

    2021  Volume 25

    Abstract: The incidence of Multiple myeloma (MM) increases with age; two-thirds of the patients are older than 65 years. Induction treatment, including new agents such as thalidomide, bortezomib, and lenalidomide followed by a conditioning regimen and upfront ... ...

    Abstract The incidence of Multiple myeloma (MM) increases with age; two-thirds of the patients are older than 65 years. Induction treatment, including new agents such as thalidomide, bortezomib, and lenalidomide followed by a conditioning regimen and upfront autologous stem cell transplantation (ASCT), has been accepted the standard treatment approach for newly diagnosed fit MM patients. We aimed to search the real-life data, the efficacy and safety of upfront ASCT following induction in patients with MM over 60 years old retrospectively. The data of MM patients who were ≥60 years old during autologous stem cell transplantation and treated at our center between 2010 and 2018 retrospectively analyzed. The study results were 63 patients included at the age of ≥ 60 years who underwent upfront ASCT. Median PFS was 15.5±2.6 months, and the median overall survival (OS) was 28.15±5 months. According to age groups, median PFS was 12±2.3 months in the 60-64 age group, 18.4±6 months in the 65-69 age group, and 26±15 months in the ≥70 age group. Median OS was 26.5±6.1 months in the 60-64 age group, 39.66±8.9 months in the 65-69 age group, and 18 months in the ≥70 age group. A significant relationship between the quantity of infused CD34+ stem cells and PFS and OS (p:0.05 and p
    Keywords autologous stem cell transplantation ; elderly ; multiple myeloma ; upfront ; 60 years old ; Medicine (General) ; R5-920
    Subject code 610
    Language Indonesian
    Publishing date 2021-06-01T00:00:00Z
    Publisher Poltekkes Kemenkes Banjarmasin
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera

    İstemi Serin / Mehmet Hilmi Doğu / Ömer Ekinci / Gülsüm Akgün Çağlıyan / Abdulkadir Baştürk / Merih Reis Aras / Sinan Demircioğlu / Burhan Turgut / Mustafa Merter / Sibel Kabukçu Hacıoğlu / Metin Bağcı / Murat Albayrak / Serdal Korkmaz / Mehmet Ali Erkurt / Mehmet Sinan Dal / Fadime Ersoy Dursun / Anıl Tombak / İsmet Aydoğdu / Turgay Ulaş /
    Fevzi Altuntaş

    İstanbul Medical Journal, Vol 24, Iss 2, Pp 120-

    2023  Volume 125

    Abstract: Introduction:Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV).Methods:A total of 34 patients with PV ...

    Abstract Introduction:Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV).Methods:A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: ≥35%) by imaging and control of hematocrit levels (≤45%) compared to baseline.Results:While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman’s rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman’s rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher’s exact test: p=0.033).Conclusion:This study shed light on the use of ruxolitinib in PV and the importance of splenomegaly on studies planned with larger patient groups.
    Keywords polycythemia vera ; ruxolitinib ; real-life data ; response ; side effect ; Medicine ; R
    Subject code 616
    Language English
    Publishing date 2023-05-01T00:00:00Z
    Publisher Galenos Yayinevi
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: Tyrosine kinase inhibitors and COVID-19

    Semih, Başcı / Tuğçe Nur, Yiğenoğlu / Mehmet Sinan, Dal / Serdal, Korkmaz / Burhan, Turgut / Fevzi, Altuntaş

    Journal of Oncology Pharmacy Practice

    2020  , Page(s) 107815522096708

    Keywords Pharmacology (medical) ; Oncology ; covid19
    Language English
    Publisher SAGE Publications
    Publishing country us
    Document type Article ; Online
    ZDB-ID 1330764-2
    ISSN 1477-092X ; 1078-1552
    ISSN (online) 1477-092X
    ISSN 1078-1552
    DOI 10.1177/1078155220967081
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4488: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Chronic Myeloid Leukemia as a Secondary Malignancy Following Treatment of Diffuse Large B-Cell Lymphoma

    Itır Şirinoğlu Demiriz / Emre Tekgündüz / Sinem Civriz Bozdağ / Fevzi Altuntaş

    Turkish Journal of Hematology, Vol 31, Iss 1, Pp 92-

    2014  Volume 94

    Keywords Internal medicine ; RC31-1245 ; Diseases of the blood and blood-forming organs ; RC633-647.5
    Language English
    Publishing date 2014-03-01T00:00:00Z
    Publisher Galenos Yayinevi
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top